查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1401978

2030 年正子斷層掃描市場預測：按產品、應用、最終用戶和地區進行的全球分析

Positron Emission Tomography Market Forecasts to 2030 - Global Analysis By Product (Radiotracers, Positron Emission Tomography (PET) Scanners, Radiopharmaceuticals and Other Products), Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據Stratistics MRC預測，2023年全球正子斷層掃描市場規模將達15億美元，預計2030年將達到27億美元，預測期內複合年成長率為8.6%。

一種稱為「正子斷層掃描」（PET）的正子醫學和生化分析技術用於測量細胞的代謝活動。透過靜脈 (IV) 管線將少量放射性葡萄糖（糖）注射到患者的靜脈中。 PET 掃描主要用於腫瘤學，對組織中的代謝活動進行影像和評估，有助於識別癌症、分期和監測治療。 PET 掃描使用放射性追蹤劑在分子層面上精確成像生理過程，幫助醫生發現問題並評估治療效果。

根據世界核能會2022年4月的更新，每年約進行4000萬次核醫學治療，放射性同位素的需求每年增加高達5%。

癌症發生率上升

對先進診斷設備的需求不斷增加，特別是隨著老年人癌症發生率的增加。 PET 影像對於腫瘤學至關重要，因為它普及於識別分子層面的代謝活動。提供有關組織代謝過程的廣泛知識有助於準確的癌症診斷、分期和監測治療反應。此外，隨著世界各地的衛生系統努力應對不斷上升的癌症發生率，PET 掃描是腫瘤學家可以用來根據每位患者的需求調整治療的重要工具。

資金成本高

PET 掃描器需要大量資金來購買、設定和維護，這使得許多醫療機構（尤其是資源有限的醫療機構）高成本。這種高資本成本是 PET 成像所需的先進技術和專用組件造成的，限制了患者和醫療保健提供者獲得 PET 掃描的機會。然而，成本負擔超出了最初的購買範圍，還包括放射性藥物用品、設備維護和合格人員培訓的持續支出。

越來越重視個人化醫療

PET 對於醫學典範轉移至關重要。 PET 影像提供了有關疾病分子特徵的重要資訊，使我們能夠更好地了解每位患者對治療的反應。 PET 可以在分子層面觀察代謝活動，幫助醫生確定最有效的治療方法並追蹤其效果。除了提高診斷準確性之外，這種個體化方法還可以幫助開發更有針對性和更有效的治療方法，最大限度地減少副作用並最大限度地提高患者的治療效果。

限制進入迴旋加速器

迴旋加速器中會產生氟 18 等短壽命放射性同位素，對於 PET 成像至關重要。然而，迴旋加速器的取得和可用性通常受到限制，特別是在某些地理區域或醫療機構。迴旋加速器的安裝和操作需要昂貴且複雜的基礎設施，因此很難在資源有限的地方建立 PET 成像中心。除了阻礙 PET 技術的進一步整合之外，迴旋加速器的使用受限也為確保放射性藥物的持續供應帶來了後勤困難。

COVID-19 的影響：

由於疫情爆發，衛生服務受到干擾，病毒控制和限制成為當務之急。為了更好地利用資源用於與大流行相關的工作，一些非緊急醫療程序，包括一些診斷成像測試，已被取消或推遲。受此影響，各種疾病的PET檢查需求暫時減少。供應鏈問題、物流困難和病患流動限制進一步限制了 PET 影像服務的取得。衛生系統在應對不斷變化的大流行環境時，面臨著滿足定期維護計劃和安裝新 PET 設備延遲的挑戰。

放射性示蹤劑場預計在預測期內達到最大值

預計輻射示踪劑領域在預測期內將是最大的。短壽命放射化學物質或放射性追蹤劑是 PET 影像的重要組成部分，可以了解體內的代謝活動。 PET 在腫瘤學、循環系統和神經病學等醫學專業中的使用不斷增加，導致對各種特定放射性追蹤劑的需求不斷成長。此外，由於放射性藥物的研究和開發，新的追蹤劑已被開發出來，提高了診斷準確性並擴大了 PET 成像的應用範圍。

預計心臟病學領域在預測期內複合年成長率最高。

預計心臟病學的複合年成長率最高。 PET 影像在心臟病學領域越來越普及，因為它能夠提供對心臟代謝和血流的高解析度功能洞察。這項技術對於檢測和治療心肌梗塞和冠狀動脈疾病等心血管疾病至關重要。此外，PET 有潛力提供有關心臟功能、活力和灌注的全面資訊，因此在循環系統醫學中引起了極大的興趣。這些資訊有助於醫生及時、準確地做出有關患者治療的決定。

佔有率最大的地區

亞太地區佔最大佔有率。該地區不斷擴大的醫療基礎設施和不斷增加的醫療技術投資支持了 PET 影像的使用。癌症和心臟病等慢性疾病的增加增加了對先進診斷設備的需求，而 PET 是其中的關鍵組成部分。亞太地區各國政府正在推動採用尖端診斷影像技術，以此作為提高醫療保健品質和可近性的手段。

複合年成長率最高的地區：

由於對精準診斷的需求不斷增加以及腫瘤學和先進診斷應用的 PET成像技術的改進等因素，預計北美地區將出現良好的成長。由於前列腺癌和乳腺癌等癌症發病率的增加，預計該地區的市場也將顯著成長。例如，美國癌症協會的2022年預測預測，2022年美國將新增1,918,030例癌症病例。

免費客製化服務：

訂閱此報告的客戶可以利用以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與企業的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計/預測/複合年成長率（註：基於可行性檢查）
  • 競爭基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 介紹
  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 產品分析
  • 應用分析
  • 最終用戶分析
  • 新興市場
  • 新型冠狀病毒感染疾病（COVID-19）的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球正子斷層掃描市場：按產品

  • 介紹
  • 放射性示踪劑
  • 正子斷層掃描 (PET) 掃描儀
  • 放射性藥物
  • 其他產品

第6章正子斷層掃描的全球市場：依應用分類

  • 介紹
  • 神經病學
    • 阿茲海默症和失智症
    • 腦腫瘤評估
    • 精神障礙
    • 運動障礙
    • 神經感受器成像
  • 心臟病學
    • 冠狀動脈疾病評估
    • 發炎成像
    • 心肌灌注顯像
    • 動脈粥狀硬化成像
    • 心內膜炎的評估
  • 感染疾病研究
  • 腫瘤學
  • 肺部疾病
  • 研究和藥物開發
  • 其他用途

第7章全球正子斷層掃描市場：依最終使用者分類

  • 介紹
  • 專科診所
  • 癌症治療中心
  • 診斷中心
  • 醫院
  • 放射中心
  • 其他最終用戶

第8章全球正子斷層掃描市場：按地區

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 中東和非洲其他地區

第9章 主要進展

  • 合約、夥伴關係、協作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務擴展
  • 其他關鍵策略

第10章 公司簡介

  • GE Healthcare
  • Philips Healthcare
  • Toshiba Corporation
  • Hitachi, Ltd
  • Rigaku Corporation
  • Siemens Healthineers
  • Positron Corporation
  • Medtronic plc
  • PerkinElmer, Inc.
  • Eckert & Ziegler Group
  • Naviscan, Inc.
  • Cubresa Inc
  • Raycan Technology Co., Ltd
  • CMR Naviscan Corporation
  • Navidea Biopharmaceuticals
  • Rotem Industries Ltd
Product Code: SMRC24498

According to Stratistics MRC, the Global Positron Emission Tomography Market is accounted for $1.5 billion in 2023 and is expected to reach $2.7 billion by 2030 growing at a CAGR of 8.6% during the forecast period. A nuclear medicine and biochemical analysis technique called "positron emission tomography" (PET) is used to measure the metabolic activity of cells. Through an intravenous (IV) line, a small quantity of radioactive glucose, or sugar, is injected into the patient's vein. PET scans are mostly utilized in oncology, where they help with cancer identification, staging, and therapy monitoring by allowing the imaging and assessment of metabolic activity in tissues. PET scans help physicians identify problems and evaluate the effectiveness of treatment by providing precise images of physiological processes at the molecular level through the use of radioactive tracers.

According to the World Nuclear Association April 2022 update, around 40 million nuclear medicine procedures are performed each year, and demand for radioisotopes is increasing by up to 5% annually.

Market Dynamics:

Driver:

Rising incidence of cancer

The need for sophisticated diagnostic instruments has increased as cancer incidence is rising, especially in elderly people. PET imaging is vital to oncology because of its popularity for identifying molecular-level metabolic activity. By offering extensive knowledge of the metabolic processes of tissues, it facilitates accurate cancer diagnosis, staging, and therapy response monitoring. Moreover, PET scans are a vital tool that oncologists can use to adapt therapies depending on the needs of each patient as healthcare systems throughout the world grapple with the rising incidence of cancer.

Restraint:

High capital cost

PET scanners have become costly for many healthcare facilities, especially those with limited resources, due to the significant financial outlays required for their purchase, setup, and maintenance. This high capital cost is a result of the sophisticated technology and particular components needed for PET imaging, which restricts the availability of PET scans for patients and healthcare providers. However, the cost burden extends beyond the original purchase and includes continuing expenditures for radiopharmaceutical supply, equipment maintenance, and qualified worker training.

Opportunity:

Growing emphasis on personalized medicine

PET is essential to the paradigm shift in medical care, which is shifting more and more toward customized and tailored therapies. PET imaging offers vital information on the distinct molecular features of diseases, enabling an improved understanding of how each patient will respond to treatment. PET helps doctors identify the most effective treatments and track their effects by allowing them to witness metabolic activity at the molecular level. In addition to improving diagnostic precision, this individualized approach helps develop more focused and effective therapies that minimize adverse effects and maximize outcomes for patients.

Threat:

Limited accessibility of cyclotrons

Short-lived radioisotopes, like fluorine-18, are generated in cyclotrons and are crucial for PET imaging. However, cyclotron accessibility and availability are frequently limited, especially in certain geographical areas or medical facilities. The installation and operation of cyclotrons require expensive and sophisticated infrastructure, which makes it difficult to establish PET imaging centers in places where these resources are limited. In addition to impeding the further integration of PET technology, this restriction on cyclotron accessibility creates logistical difficulties in ensuring an ongoing supply of radiopharmaceuticals.

COVID-19 Impact:

Healthcare services were disrupted as a result of the epidemic, and controlling and restricting the virus gained precedence. Several non-urgent medical procedures-such as certain diagnostic imaging studies-were canceled or postponed in order to use resources more effectively for pandemic-related initiatives. This resulted in a brief decrease in demand for the routine use of PET scans for a variety of medical disorders. PET imaging services' accessibility was further limited by supply chain problems, logistical difficulties, and patient mobility limitations. Healthcare systems faced difficulties adhering to regular maintenance schedules and delays in the installation of new PET equipment as they adjusted to the changing pandemic environment.

The radiotracers segment is expected to be the largest during the forecast period

Radiotracers segment is expected to be the largest during the forecast period. Short-lived radioactive chemicals, or radiotracers, are essential parts of PET imaging that make the body's metabolic activities accessible. The growing need for a variety of specific radiotracers is a result of the growing uses of PET in oncology, cardiology, and neurology, among other medical specialties. Moreover, novel tracers have been developed as a result of developments in radiopharmaceutical research and development, improving diagnostic precision and broadening the application of PET imaging.

The cardiology segment is expected to have the highest CAGR during the forecast period

Cardiology segment is expected to have the highest CAGR. PET imaging is becoming more and more popular in cardiology due to its incredible ability to offer high-resolution, functional insights into heart metabolism and blood flow. When it comes to the detection and treatment of cardiovascular diseases, including myocardial infarction and coronary artery disease, this technology is essential. Moreover, because PET may provide comprehensive information about heart function, viability, and perfusion, it is highly sought after in cardiology. This information helps doctors make timely and precise decisions regarding patient care.

Region with largest share:

Asia Pacific region dominated the largest share. PET imaging use is being aided by the region's expanding healthcare infrastructure and rising medical technology investments. Growing rates of chronic illnesses, such as cancer and heart problems, are driving up the need for sophisticated diagnostic instruments, of which PET is an essential component. Governments around Asia-Pacific are promoting the incorporation of cutting-edge imaging technologies as a means of enhancing healthcare quality and accessibility.

Region with highest CAGR:

Due to factors including the growing need for precision diagnostics and the technological improvements in PET imaging for oncology and advanced diagnostic applications, the North American region is projected to have lucrative growth. Significant market growth in the region is also anticipated due to the increasing incidence of cancer cases, including prostate and breast cancer. For instance, according to the American Cancer Society's 2022 forecast, 1,918,030 new cases of cancer are expected in the United States in 2022.

Key players in the market:

Some of the key players in Positron Emission Tomography market include GE Healthcare, Philips Healthcare, Toshiba Corporation, Hitachi, Ltd, Rigaku Corporation, Siemens Healthineers, Positron Corporation, Medtronic plc, PerkinElmer, Inc., Eckert & Ziegler Group, Naviscan, Inc., Cubresa Inc, Raycan Technology Co., Ltd, CMR Naviscan Corporation, Navidea Biopharmaceuticals and Rotem Industries Ltd.

Key Developments:

In August 2022, Positron Corporation, a nuclear medicine PET imaging device system and clinical services company, purchased its first PET-CT system and was on its way from its partner Neusoft Medical Systems. Positron's "Affinity PET-CT" system is on its way from China to its validation partner in the United States.

In July 2022, Radialis Inc. received clearance to market the Radialis PET Imager, an organ-targeted positron emission tomography (PET) system, in the United States. The advanced sensitivity of the Radialis PET Imager to radiotracer enables the system to produce functional images with high spatial resolution, expanding the insight available from molecular imaging.

Products Covered:

  • Radiotracers
  • Positron Emission Tomography (PET) Scanners
  • Radiopharmaceuticals
  • Other Products

Applications Covered:

  • Neurology
  • Cardiology
  • Infectious Diseases
  • Oncology
  • Pulmonary Disorders
  • Research and Drug Development
  • Other Applications

End Users Covered:

  • Specialty Clinics
  • Cancer Treatment Centers
  • Diagnostic Centers
  • Hospitals
  • Radiology Centers
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Positron Emission Tomography Market, By Product

  • 5.1 Introduction
  • 5.2 Radiotracers
  • 5.3 Positron Emission Tomography (PET) Scanners
  • 5.4 Radiopharmaceuticals
  • 5.5 Other Products

6 Global Positron Emission Tomography Market, By Application

  • 6.1 Introduction
  • 6.2 Neurology
    • 6.2.1 Alzheimer's Disease and Dementia
    • 6.2.2 Brain Tumor Evaluation
    • 6.2.3 Psychiatric Disorders
    • 6.2.4 Movement Disorders
    • 6.2.5 Neuroreceptor Imaging
  • 6.3 Cardiology
    • 6.3.1 Coronary Artery Disease Evaluation
    • 6.3.2 Inflammation Imaging
    • 6.3.3 Myocardial Perfusion Imaging
    • 6.3.4 Atherosclerosis Imaging
    • 6.3.5 Endocarditis Evaluation
  • 6.4 Infectious Diseases
  • 6.5 Oncology
  • 6.6 Pulmonary Disorders
  • 6.7 Research and Drug Development
  • 6.8 Other Applications

7 Global Positron Emission Tomography Market, By End User

  • 7.1 Introduction
  • 7.2 Specialty Clinics
  • 7.3 Cancer Treatment Centers
  • 7.4 Diagnostic Centers
  • 7.5 Hospitals
  • 7.6 Radiology Centers
  • 7.7 Other End Users

8 Global Positron Emission Tomography Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 GE Healthcare
  • 10.2 Philips Healthcare
  • 10.3 Toshiba Corporation
  • 10.4 Hitachi, Ltd
  • 10.5 Rigaku Corporation
  • 10.6 Siemens Healthineers
  • 10.7 Positron Corporation
  • 10.8 Medtronic plc
  • 10.9 PerkinElmer, Inc.
  • 10.10 Eckert & Ziegler Group
  • 10.11 Naviscan, Inc.
  • 10.12 Cubresa Inc
  • 10.13 Raycan Technology Co., Ltd
  • 10.14 CMR Naviscan Corporation
  • 10.15 Navidea Biopharmaceuticals
  • 10.16 Rotem Industries Ltd

List of Tables

  • Table 1 Global Positron Emission Tomography Market Outlook, By Region (2021-2030) ($MN)
  • Table 2 Global Positron Emission Tomography Market Outlook, By Product (2021-2030) ($MN)
  • Table 3 Global Positron Emission Tomography Market Outlook, By Radiotracers (2021-2030) ($MN)
  • Table 4 Global Positron Emission Tomography Market Outlook, By Positron Emission Tomography (PET) Scanners (2021-2030) ($MN)
  • Table 5 Global Positron Emission Tomography Market Outlook, By Radiopharmaceuticals (2021-2030) ($MN)
  • Table 6 Global Positron Emission Tomography Market Outlook, By Other Products (2021-2030) ($MN)
  • Table 7 Global Positron Emission Tomography Market Outlook, By Application (2021-2030) ($MN)
  • Table 8 Global Positron Emission Tomography Market Outlook, By Neurology (2021-2030) ($MN)
  • Table 9 Global Positron Emission Tomography Market Outlook, By Alzheimer's Disease and Dementia (2021-2030) ($MN)
  • Table 10 Global Positron Emission Tomography Market Outlook, By Brain Tumor Evaluation (2021-2030) ($MN)
  • Table 11 Global Positron Emission Tomography Market Outlook, By Psychiatric Disorders (2021-2030) ($MN)
  • Table 12 Global Positron Emission Tomography Market Outlook, By Movement Disorders (2021-2030) ($MN)
  • Table 13 Global Positron Emission Tomography Market Outlook, By Neuroreceptor Imaging (2021-2030) ($MN)
  • Table 14 Global Positron Emission Tomography Market Outlook, By Cardiology (2021-2030) ($MN)
  • Table 15 Global Positron Emission Tomography Market Outlook, By Coronary Artery Disease Evaluation (2021-2030) ($MN)
  • Table 16 Global Positron Emission Tomography Market Outlook, By Inflammation Imaging (2021-2030) ($MN)
  • Table 17 Global Positron Emission Tomography Market Outlook, By Myocardial Perfusion Imaging (2021-2030) ($MN)
  • Table 18 Global Positron Emission Tomography Market Outlook, By Atherosclerosis Imaging (2021-2030) ($MN)
  • Table 19 Global Positron Emission Tomography Market Outlook, By Endocarditis Evaluation (2021-2030) ($MN)
  • Table 20 Global Positron Emission Tomography Market Outlook, By Infectious Diseases (2021-2030) ($MN)
  • Table 21 Global Positron Emission Tomography Market Outlook, By Oncology (2021-2030) ($MN)
  • Table 22 Global Positron Emission Tomography Market Outlook, By Pulmonary Disorders (2021-2030) ($MN)
  • Table 23 Global Positron Emission Tomography Market Outlook, By Research and Drug Development (2021-2030) ($MN)
  • Table 24 Global Positron Emission Tomography Market Outlook, By Other Applications (2021-2030) ($MN)
  • Table 25 Global Positron Emission Tomography Market Outlook, By End User (2021-2030) ($MN)
  • Table 26 Global Positron Emission Tomography Market Outlook, By Specialty Clinics (2021-2030) ($MN)
  • Table 27 Global Positron Emission Tomography Market Outlook, By Cancer Treatment Centers (2021-2030) ($MN)
  • Table 28 Global Positron Emission Tomography Market Outlook, By Diagnostic Centers (2021-2030) ($MN)
  • Table 29 Global Positron Emission Tomography Market Outlook, By Hospitals (2021-2030) ($MN)
  • Table 30 Global Positron Emission Tomography Market Outlook, By Radiology Centers (2021-2030) ($MN)
  • Table 31 Global Positron Emission Tomography Market Outlook, By Other End Users (2021-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.